DDX17 promotes the growth and metastasis of lung adenocarcinoma

被引:9
|
作者
Liu, Xiaohui [1 ,2 ]
Li, Lu [1 ,2 ]
Geng, Chengjie [1 ,2 ]
Wen, Shiyuan [1 ,2 ]
Zhang, Cuiqiong [1 ,2 ]
Deng, Chunmiao [1 ,2 ]
Gao, Xuejuan [1 ,2 ]
Zhang, Gong [1 ,2 ]
He, Qing-Yu [1 ,2 ]
Liu, Langxia [1 ,2 ]
机构
[1] Jinan Univ, Inst Life & Hlth Engn, Key Lab Funct Prot Res Guangdong Higher Educ Inst, Guangzhou 510632, Peoples R China
[2] Jinan Univ, Inst Life & Hlth Engn, MOE Key Lab Tumor Mol Biol, Guangzhou 510632, Peoples R China
关键词
RNA HELICASES; CANCER CELLS; AUTOPHAGY; PROTEINS; P72; EXPRESSION; INVASION; PROLIFERATION; DEGRADATION; INVOLVEMENT;
D O I
10.1038/s41420-022-01215-x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
DEAD box RNA helicase 17 (DDX17) has been shown to be an RNA binding protein involved in RNA metabolism and associated with cancer progression. However, the biological role of DDX17 in the pathogenesis of lung adenocarcinoma (LUAD) has not been well characterized. Here, we demonstrated that DDX17 promoted the proliferation, migration and invasion of H1299 and A549 lung adenocarcinoma cells. Analyses of public datasets showed that DDX17 is upregulated in LUAD specimens. Our tumor xenograft models confirmed the in vivo promoting role of DDX17 in the growth and metastasis of LUAD. Mechanistic analyses further revealed that DDX17 protein interacts with the mRNA of MYL9 and MAGEA6 and upregulates their levels. MYL9 could mediate the function of DDX17 to regulate the actin cytoskeleton rearrangement and cell adhesion, particularly by modulating the stress fiber and focal adhesion formation, whereas DDX17 might inhibit the autophagy process through MAGEA6/AMPK alpha 1 axis in LUAD cells. Collectively, our study revealed the oncogenic role and pathways of DDX17 in LUAD.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] DDX17 promotes hepatocellular carcinoma progression via inhibiting Klf4 transcriptional activity
    Xue, Ying
    Jia, Xuebing
    Li, Changcan
    Zhang, Ke
    Li, Lei
    Wu, Jinhuan
    Yuan, Jian
    Li, Qi
    CELL DEATH & DISEASE, 2019, 10 (11)
  • [12] The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness
    Wu, Kou-Juey
    BIOMEDICAL JOURNAL, 2020, 43 (02) : 107 - 114
  • [13] DDX17: Structured RNA recognition drives diverse outputs
    Moy, Ryan H.
    Cherry, Sara
    CELL CYCLE, 2014, 13 (22) : 3467 - 3468
  • [14] RNA Specificity and Autoregulation of DDX17, a Modulator of MicroRNA Biogenesis
    Ngo, Tri D.
    Partin, Alexander C.
    Nam, Yunsun
    CELL REPORTS, 2019, 29 (12): : 4024 - +
  • [15] DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin
    Li, Kai
    Mo, Chunfen
    Gong, Di
    Chen, Yan
    Huang, Zhao
    Li, Yanyan
    Zhang, Jie
    Huang, Lugang
    Li, Yuan
    Fuller-Pace, Frances V.
    Lin, Ping
    Wei, Yuquan
    CANCER LETTERS, 2017, 400 : 194 - 202
  • [16] Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17
    Wu, Xing-Cheng
    Yan, Wei-Gang
    Ji, Zhi-Gang
    Zheng, Guo-Yang
    Liu, Guang-Hua
    ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) : 1752 - 1765
  • [17] DDX47 promotes cell proliferation and migration in lung adenocarcinoma
    Chen, Yang
    Zeng, Lizhong
    Wang, Wei
    Yuan, Jingyan
    Sun, Ruiying
    Yang, Shuanying
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 234
  • [18] δ-Catenin promotes tumorigenesis and metastasis of lung adenocarcinoma
    Huang, Fei
    Chen, Junying
    Wang, Zeng
    Lan, Ruilong
    Fu, Lengxi
    Zhang, Lurong
    ONCOLOGY REPORTS, 2018, 39 (02) : 809 - 817
  • [19] DDX17 helicase promotes resolution of R-loop-mediated transcription-replication conflicts in human cells
    Boleslavska, Barbora
    Oravetzova, Anna
    Shukla, Kaustubh
    Nascakova, Zuzana
    Ibini, Oluwakemi Ngozi
    Hasanova, Zdenka
    Andrs, Martin
    Kanagaraj, Radhakrishnan
    Dobrovolna, Jana
    Janscak, Pavel
    NUCLEIC ACIDS RESEARCH, 2022, 50 (21) : 12274 - 12290
  • [20] DDX17在癌症中的研究进展
    庞凯丹
    李洋
    现代肿瘤医学, 2023, 31 (05) : 975 - 979